

MEDWATCH

3500A Facsimile

For use by user-facilities,
importers, distributors and manufacturers
for MANDATORY reporting

Mfr Report #	(b) (6)
UF/Importer Report #	
FDA Use Only	

Page 1 of 4

A. PATIENT INFORMATION			
1. Patient Identifier US3542108	2. Age at Time of Event: 46 Years or Date of Birth: (b) (6)/1974	3. Sex <input checked="" type="checkbox"/> Female <input type="checkbox"/> Male	4. Weight ____ lbs or ____ kgs
In confidence			
B. ADVERSE EVENT OR PRODUCT PROBLEM			
1. <input checked="" type="checkbox"/> Adverse Event and/or <input type="checkbox"/> Product Problem (e.g., defects/malfunctions)			
2. Outcomes Attributed to Adverse Event (Check all that apply)			
<input type="checkbox"/> Death: _____ (mm/dd/yyyy) <input type="checkbox"/> Life-threatening <input type="checkbox"/> Hospitalization - initial or prolonged <input type="checkbox"/> Required Intervention to Prevent Permanent Impairment/Damage (Devices)			
<input type="checkbox"/> Disability or Permanent Damage <input type="checkbox"/> Congenital Anomaly/Birth Defect <input checked="" type="checkbox"/> Other Serious (Important Medical Events)			
3. Date of Event (mm/dd/yyyy) 09/30/2020		4. Date of This Report (mm/dd/yyyy) 11/22/2020	
5. Describe Event or Problem Event Verbatim [LOWER LEVEL TERM] (Related symptoms if any separated by commas) CHEEK SWELLING, BILATERAL [Cheek swelling] CHEEK SWELLING, BILATERAL [Cheek swelling] Case Description: Cohort: >=18 and <65 years and not at risk Date of Birth: 1974 (b) (6) AE: CHEEK SWELLING, BILATERAL Start Date: 20200930 SAE Description: 46 YEAR OLD FEMALE ENROLLED AND RECEIVED 1ST DOSE OF VACCINE/PLACEBO ON 31AUG2020; 2ND DOSE ADMINISTERED ON 29SEP2020. STARTING NIGHT OF 29SEP2020 HAD INJECTION SITE PAIN, THROUGH 30SEP2020. ALSO MODERATE MYALGIAS & ARTHRALGIAS 30SEP-01OCT2020. AWOKE continued in additional info section...			
6. Relevant Tests/Laboratory Data, Including Dates			
7. Other Relevant History, Including Preexisting Medical Conditions (e.g. allergies, race, pregnancy, smoking and alcohol use, hepatic/renal dysfunction, etc.) Race: White #1 10/13/2005 to 10/13/2005 Procedure, (Continued) #2 10/13/2005 to 10/13/2005 Historical Condition, (Continued) #3 06/30/2008 to 06/30/2008 Procedure, (Continued) continued in additional info section...			

C. SUSPECT PRODUCT(S)			
1. Name (Give labeled strength & mfr/labeler) (Regimens Continued)			
#1. mRNA-1273 vs Placebo (Code not broken)			
#2.			
2. Dose, Frequency & Route Used		3. Therapy Dates (if unknown, give duration) from/to (or best estimate)	
#1. Blinded, Information withheld.		#1. 08/31/2020 to 08/31/2020	
#2.		#2.	
4. Diagnosis for Use (Indication)		5. Event Abated After Use Stopped or Dose Reduced?	
#1. COVID-19 (Continued)		#1. <input type="checkbox"/> Yes <input type="checkbox"/> No <input checked="" type="checkbox"/> Doesn't Apply	
#2.		#2. <input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Doesn't Apply	
6. Lot #	7. Exp. Date	8. Event Reappeared After Reintroduction?	
#1. Blinded	#1. Blinded	#1. <input type="checkbox"/> Yes <input type="checkbox"/> No <input checked="" type="checkbox"/> Doesn't Apply	
#2.	#2.	#2. <input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Doesn't Apply	
9. NDC# or Unique ID			
10. Concomitant Medical Products and Therapy Dates (Exclude treatment of event) 1) CYMBALTA (DULOXETINE HYDROCHLORIDE) --/--/2018 to ongoing continued in additional info section...			
G. ALL MANUFACTURERS			
1. Contact Office (and Manufacturing Site for Devices)		2. Phone Number	
Name ModernaTX, Inc. David Martin MD.		617-335-1804	
Address 200 Technology Square Cambridge, MA 02139 United States of America		3. Report Source (Check all that apply)	
Email Address		<input type="checkbox"/> Foreign <input checked="" type="checkbox"/> Study <input type="checkbox"/> Literature <input type="checkbox"/> Consumer <input checked="" type="checkbox"/> Health Professional <input type="checkbox"/> User Facility <input type="checkbox"/> Company Representative <input type="checkbox"/> Distributor <input type="checkbox"/> Other: _____	
4. Date Received by Manufacturer (mm/dd/yyyy) 11/19/2020	5. (A)NDA # IND # 019635 BLA # PMA/ 510(k) # Combination Product <input type="checkbox"/> Yes Pre-1938 <input type="checkbox"/> Yes OTC Product <input type="checkbox"/> Yes		
6. If IND, Give Protocol # mRNA-1273-P301			
7. Type of Report (Check all that apply)			
<input type="checkbox"/> 5-day <input type="checkbox"/> 30-day <input type="checkbox"/> 7-day <input type="checkbox"/> Periodic <input type="checkbox"/> 10-day <input type="checkbox"/> Initial <input type="checkbox"/> 15-day <input checked="" type="checkbox"/> Follow-up #2			
9. Manufacturer Report Number (b) (6)	8. Adverse Event Term(s) Cheek swelling, Cheek swelling		
E. INITIAL REPORTER			
1. Name and Address Dr DAVID DIEMERT George Washington University 2300 EYE STREET NW WASHINGTON, DC 20037 UNITED STATES			
Phone # (b) (6)		Email Address (b) (6) @gwu.edu	
2. Health Professional? <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	3. Occupation Physician	4. Initial Reporter Also Sent Report to FDA <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No <input type="checkbox"/> Unk	

Submission of a report does not constitute an admission that medical personnel, user facility, distributor, manufacturer or product caused or contributed to the event

Mir Report #	(b) (6)
UF/Importer Report #	
FDA Use Only	

ADDITIONAL INFORMATION**B5. EVENT DESCRIPTION (Continued)**

30SEP2020 WITH SIGNIFICANT BILATERAL CHEEK SWELLING; NO RASH, PAIN, TENDERNESS, ORAL OR RESPIRATORY SYMPTOMS. NO FEVER/CHILLS. FELT ABSOLUTELY WELL ASIDE FROM UNSIGHTLY CHEEK SWELLING. NO NEW MEDS, FOODS, CREAMS, TOOTHPASTE, ETC. OF NOTE, HAD BILATERAL VOLUMA CHEEK INJECTIONS IN MARCH 2020 (FIRST AND ONLY ADMINISTRATION), WITHOUT INCIDENT.

NO RELIEF FROM BENADRYL (50MG QD 01-03OCT2020). DUE TO ONGOING SWELLING, STARTED ON SOLUMEDROL DOSE PACK (4MG TABS) ON 03OCT2020 (THROUGH 07OCT2020). CONSIDERABLY IMPROVED BY 04OCT2020 WITH COMPLETE RESOLUTION OF SWELLING BY 05OCT2020. NO RECURRENCE. WAS NOT ORIGINALLY REPORTED AS AN SAE BUT DUE TO RECENT MEDWATCH REPORT (b) (6), PARTICIPANT US3322329) OF A VERY SIMILAR EVENT IN ANOTHER STUDY PARTICIPANT POST-VOLUMA FILLER INJECTION, I AM NOW SUBMITTING THIS EVENT AS AN UNEXPECTED, RELATED SAE (IN MY CLINICAL JUDGEMENT).

Other medically important event: Yes

Action Taken: Not Applicable

Action Taken ER Visit: 1

Related to procedure: Not Related

Severity: Grade 2/Moderate

Study Drug iterations first and closest:

Study Drug First Start Date: 20200831

Study Drug First Start Time:

Study Drug Latest Start Date: 20200929

Study Drug Latest Start Time:

This 46-year-old, White female subject (US3542108) was participating in A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older (mRNA-1273-P301) and experienced cheek swelling, bilateral.

The subject's medical history, as provided by the investigator, included c-section x2, mastectomy - flap reconstruction and anxiety. Concomitant medications reported included duloxetine hydrochloride.

In Mar 2020, she had bilateral Voluma (hyaluronic acid) cheek injections (first and only administration) without incident.

The subject was allocated to receive. The subject received the first dose of intramuscular mRNA-1273 or placebo for SARS-CoV-2 vaccination on 31 Aug 2020. The subject's last dose of study drug prior to event onset was on 29 Sep 2020.

On 29 Sep 2020, the subject experienced injection site pain at night through the next day.

On 30 Sep 2020, she experienced the medically important event of cheek swelling, bilateral. She woke up with significant bilateral cheek swelling; no rash, pain, tenderness, oral or respiratory symptoms. She had no fever or chills and felt well aside from unsightly cheek swelling. She had no new medications, foods, creams, toothpaste, etc.

On 01 Oct 2020, treatment included oral diphenhydramine 50 mg daily with no relief.

On 03 Oct 2020, she started oral methylprednisolone 4 mg tabs.

On 04 Oct 2020, the subject considerably improved.

Action taken with study drug in response to the event was not applicable, as the subject had already received both doses per protocol.

The event, cheek swelling, bilateral, was considered resolved on 05 Oct 2020 and had no recurrence.

The investigator assessed the event, cheek swelling, bilateral, as related to study drug and not related to study procedure.

Analysis of Similar Events: On 09-Nov-2020, the safety database was searched for events similar to Swelling face using the following
FDA-CBER-2022-1614-4434508

Mfr Report #	(b) (6)
UF/Importer Report #	
FDA Use Only	

search criteria: PT: Facial swelling, Swelling face; SMQ: Angioedema. As of 09-Nov-2020 under IND 019745 for mRNA-1273, 5 similar events were retrieved, including the current index case. One of these cases reporting the following events were previously submitted as IND Safety Reports: Swelling face (1): MCN# (b) (6)

There were four cases were non-IND Safety Reports reporting the following events: Oedema peripheral (1) (b) (6), Angioedema (1) (b) (6), Swelling face (1) (b) (6), Laryngeal oedema (1) (b) (6).

(b) (6): An event of swelling face was reported in a subject with a recent dental history of root canal. The facial swelling occurred 7 days after blinded study vaccine administration and 14 days after root canal. A consultant ENT suggested the event may be due to an odontogenic infection.

(b) (6): An event of bilateral ankle edema (and concurrent shortness of breath) was reported in a subject with medical history of breast cancer and pre-existing diabetes mellitus type 2 and hypertension. The event short bilateral ankle edema occurred 1 month 8 days after the blinded study vaccine and 11 days after the last vaccine administration.

(b) (6): An event of angioedema was reported in a subject taking concomitant lisinopril for hypertension. The event occurred 21 days after the first dose of the study medication. The event resolved 2 days later. The event is more likely explained by the subject's concomitant use of lisinopril known to cause angioedema.

(b) (6): An event of laryngeal edema was reported in a subject with medical history of sulfa allergy (hives). The event occurred 4 days after the second dose of blinded study medication administration. The event of laryngeal edema was likely associated with lisinopril therapy which was discontinued due to adverse event.

Assessment of Relationship: Based on review of available data, the Sponsor cannot rule out a possible cause and effect relationship between administration of blinded study vaccine and the occurrence facial swelling.

After review of the clinical details and investigator comments pertaining to this adverse event, and based upon experience to date, the Sponsor does not believe that changes to the conduct of this clinical trial are warranted. The Company will continue to monitor these and other serious adverse events reported in association with the IMP and will communicate any relevant changes to the protocol, Informed Consent Form, Investigator's Brochure, and/or Core Safety Information.

Case Comment/Sender's Comment:

Company Comment: This case concerns a 46-year-old, White female subject with May 2020 medical history of bilateral Voluma (hyaluronic acid) cheek injections (first and only administration) without incident, who experienced an unexpected event of cheek swelling, bilateral. The event occurred 1 month after the first dose of blinded study vaccine administration and 1 day after the last dose administration. The event was considered related to the study vaccine in agreement with the Investigator's assessment.

B7. OTHER RELEVANT HISTORY

#	Start/Stop Date	Condition Type / Condition	Notes
1	10/13/2005 10/13/2005	Procedure Caesarean section	
2	10/13/2005 10/13/2005	Historical Condition C SECTION	
3	06/30/2008 06/30/2008	Procedure Caesarean section	
4	06/30/2008 06/30/2008	Historical Condition C SECTION	
5	04/--/2017 04/--/2017	Procedure Mastectomy	FLAP RECONSTRUCTION

Mir Report #	(b) (6)
UF/Importer Report #	
FDA Use Only	

6	04/--/2017 04/--/2017	Historical Condition MASTECTOMY - FLAP RECONSTRUCTION
---	--------------------------	---

7	--/--/2018 Ongoing	Historical Condition Anxiety
---	-----------------------	---------------------------------

C4. DIAGNOSIS FOR USE (Continued)

#1:COVID-19 vaccination (COVID-19 immunisation)

C10. CONCOMITANT MEDICAL PRODUCTS (Continued)

- 2) BENADRYL 10/01/2020 to 10/03/2020
- 3) BENADRYL 10/17/2020 to 10/17/2020
- 4) SOLUMEDROL DOSE PAK 10/03/2020 to 10/07/2020
- 5) TYLENOL (PARACETAMOL) 09/30/2020 to 10/03/2020

Block C - Additional Dosage Regimens

Suspect Product	2. Dose, frequency & route used	3. Therapy dates (if unknown, give duration)	6. Lot #	7. Exp. date
#1 mRNA-1273 vs Placebo Regimen # 2	Blinded, Information withheld.	09/29/2020 to 09/29/2020	Blinded	Blinded